Autolus Therapeutics (AUTL) Stock Forecast, Price Target & Predictions
AUTL Stock Forecast
Autolus Therapeutics stock forecast is as follows: an average price target of $9.50 (represents a 136.91% upside from AUTL’s last price of $4.01) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
AUTL Price Target
The average price target for Autolus Therapeutics (AUTL) is $9.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $8.00. This represents a potential 136.91% upside from AUTL's last price of $4.01.
AUTL Analyst Ratings
According to 3 Wall Street analysts, Autolus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AUTL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Autolus Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 20, 2024 | Yanan Zhu | Wells Fargo | $8.00 | $4.39 | 82.23% | 99.50% |
| Apr 08, 2024 | Asthika Goonewardene | Truist Financial | $11.00 | $5.53 | 98.92% | 174.31% |
| Mar 15, 2024 | Asthika Goonewardene | Truist Financial | $10.00 | $5.82 | 71.82% | 149.38% |
The latest Autolus Therapeutics stock forecast, released on May 20, 2024 by Yanan Zhu from Wells Fargo, set a price target of $8.00, which represents a 82.23% increase from the stock price at the time of the forecast ($4.39), and a 99.50% increase from AUTL last price ($4.01).
Autolus Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $9.67 |
| Last Closing Price | $4.01 | $4.01 | $4.01 |
| Upside/Downside | -100.00% | -100.00% | 141.15% |
In the current month, the average price target of Autolus Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Autolus Therapeutics's last price of $4.01. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 17, 2024 | Needham | Buy | Buy | Hold |
| May 20, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Mar 18, 2024 | Needham | Buy | Buy | Hold |
| Mar 08, 2023 | Piper Sandler | Buy | Buy | Hold |
| Dec 09, 2022 | Needham | Buy | Buy | Hold |
Autolus Therapeutics's last stock rating was published by Needham on Jun 17, 2024. The company gave AUTL a "Buy" rating, the same as its previous rate.
Autolus Therapeutics Financial Forecast
Autolus Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $406.00K | - | $1.29M | $3.83M | $2.37M | - |
| Avg Forecast | $44.28M | $37.73M | $26.38M | $19.94M | $20.10M | $16.28M | $12.88M | $10.13M | $168.75K | $193.75K | $93.75K | $29.01M | $358.40K | $624.80K | $136.50K | $379.29K | $11.18M | $144.29K | $240.56K |
| High Forecast | $44.28M | $37.73M | $26.38M | $19.94M | $20.10M | $16.28M | $12.88M | $10.13M | $168.75K | $193.75K | $93.75K | $29.01M | $358.40K | $624.80K | $136.50K | $379.29K | $11.18M | $144.29K | $240.56K |
| Low Forecast | $44.28M | $37.73M | $26.38M | $19.94M | $20.10M | $16.28M | $12.88M | $10.13M | $168.75K | $193.75K | $93.75K | $29.01M | $358.40K | $624.80K | $136.50K | $379.29K | $11.18M | $144.29K | $240.56K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | - | 3.41% | 0.34% | 16.42% | - |
Autolus Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $358.40K, with a low forecast of $358.40K, and a high forecast of $358.40K. AUTL's average Quarter revenue forecast represents a -11.72% decrease compared to the company's last Quarter revenue of $406.00K (Sep 23).
Autolus Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-40.89M | $-44.01M | $-42.47M | $-33.21M | $-26.45M | $-45.28M | - |
| Avg Forecast | $-44.28M | $-37.73M | $-26.38M | $-19.94M | $-20.10M | $-16.28M | $-12.88M | $-10.13M | $-168.75K | $-193.75K | $-93.75K | $-61.91M | $-358.40K | $-624.80K | $-136.50K | $-56.28M | $-11.18M | $-37.57M | $-240.56K |
| High Forecast | $-44.28M | $-37.73M | $-26.38M | $-19.94M | $-20.10M | $-16.28M | $-12.88M | $-10.13M | $-168.75K | $-193.75K | $-93.75K | $-49.53M | $-358.40K | $-624.80K | $-136.50K | $-45.03M | $-11.18M | $-30.06M | $-240.56K |
| Low Forecast | $-44.28M | $-37.73M | $-26.38M | $-19.94M | $-20.10M | $-16.28M | $-12.88M | $-10.13M | $-168.75K | $-193.75K | $-93.75K | $-74.29M | $-358.40K | $-624.80K | $-136.50K | $-67.54M | $-11.18M | $-45.08M | $-240.56K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 114.08% | 70.44% | 311.11% | 0.59% | 2.37% | 1.21% | - |
undefined analysts predict AUTL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Autolus Therapeutics's previous annual EBITDA (undefined) of $NaN.
Autolus Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-77.17M | $-45.85M | $-45.55M | $-39.81M | $-26.95M | $-42.77M | - |
| Avg Forecast | $-31.14M | $-37.58M | $-49.07M | $-46.85M | $-50.23M | $-54.67M | $-59.74M | $-58.87M | $-54.01M | $-56.99M | $-51.74M | $-59.09M | $-67.27M | $-66.38M | $-59.45M | $-53.72M | $-71.44M | $-33.69M | $-93.31M |
| High Forecast | $-31.14M | $-37.58M | $-49.07M | $-46.85M | $-50.23M | $-54.67M | $-59.74M | $-58.87M | $-54.01M | $-51.56M | $-51.74M | $-47.27M | $-59.51M | $-66.38M | $-59.45M | $-42.98M | $-71.44M | $-26.95M | $-93.31M |
| Low Forecast | $-31.14M | $-37.58M | $-49.07M | $-46.85M | $-50.23M | $-54.67M | $-59.74M | $-58.87M | $-54.01M | $-59.70M | $-51.74M | $-70.91M | $-75.04M | $-66.38M | $-59.45M | $-64.46M | $-71.44M | $-40.43M | $-93.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 0.69% | 0.77% | 0.74% | 0.38% | 1.27% | - |
Autolus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AUTL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Autolus Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $15.73M | $10.61M | $11.12M | $9.28M | $7.41M | $8.23M | - |
| Avg Forecast | $1.78B | $1.51B | $1.06B | $799.82M | $806.13M | $652.89M | $516.50M | $406.41M | $6.77M | $7.77M | $3.76M | $12.73M | $14.38M | $25.06M | $5.48M | $15.21M | $448.47M | $5.79M | $9.65M |
| High Forecast | $1.78B | $1.51B | $1.06B | $799.82M | $806.13M | $652.89M | $516.50M | $406.41M | $6.77M | $7.77M | $3.76M | $15.28M | $14.38M | $25.06M | $5.48M | $15.21M | $448.47M | $5.79M | $9.65M |
| Low Forecast | $1.78B | $1.51B | $1.06B | $799.82M | $806.13M | $652.89M | $516.50M | $406.41M | $6.77M | $7.77M | $3.76M | $10.19M | $14.38M | $25.06M | $5.48M | $15.21M | $448.47M | $5.79M | $9.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.42% | 2.03% | 0.61% | 0.02% | 1.42% | - |
Autolus Therapeutics's average Quarter SG&A projection for Mar 24 is $12.73M, based on 1 Wall Street analysts, with a range of $10.19M to $15.28M. The forecast indicates a -19.03% fall compared to AUTL last annual SG&A of $15.73M (Dec 23).
Autolus Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $-0.26 | $-0.26 | $-0.23 | $-0.30 | $-0.47 | - |
| Avg Forecast | $-0.12 | $-0.14 | $-0.18 | $-0.18 | $-0.19 | $-0.21 | $-0.22 | $-0.22 | $-0.20 | $-0.21 | $-0.19 | $-0.08 | $-0.25 | $-0.25 | $-0.22 | $-0.27 | $-0.27 | $-0.47 | $-0.42 |
| High Forecast | $-0.12 | $-0.14 | $-0.18 | $-0.18 | $-0.19 | $-0.21 | $-0.22 | $-0.22 | $-0.20 | $-0.19 | $-0.19 | $-0.08 | $-0.22 | $-0.25 | $-0.22 | $-0.27 | $-0.27 | $-0.47 | $-0.42 |
| Low Forecast | $-0.12 | $-0.14 | $-0.18 | $-0.18 | $-0.19 | $-0.21 | $-0.22 | $-0.22 | $-0.20 | $-0.22 | $-0.19 | $-0.08 | $-0.28 | $-0.25 | $-0.22 | $-0.27 | $-0.27 | $-0.47 | $-0.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.74% | 1.04% | 1.16% | 0.86% | 1.12% | 1.00% | - |
According to undefined Wall Street analysts, Autolus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AUTL previous annual EPS of $NaN (undefined).
Autolus Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.65 | $3.67 | 464.62% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| RZLT | Rezolute | $4.35 | $12.50 | 187.36% | Buy |
| INZY | Inozyme Pharma | $4.98 | $14.00 | 181.12% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| AUTL | Autolus Therapeutics | $4.01 | $9.50 | 136.91% | Buy |
| CELC | Celcuity | $15.06 | $31.50 | 109.16% | Buy |
| LYRA | Lyra Therapeutics | $0.27 | $0.50 | 85.19% | Hold |
| APLS | Apellis Pharmaceuticals | $41.05 | $75.81 | 84.68% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| TERN | Terns Pharmaceuticals | $7.81 | $12.50 | 60.05% | Buy |
| BOLT | Bolt Biotherapeutics | $0.65 | $1.00 | 53.85% | Hold |
| AMLX | Amylyx Pharmaceuticals | $2.37 | $3.33 | 40.51% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
AUTL Forecast FAQ
Is Autolus Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Autolus Therapeutics (AUTL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of AUTL's total ratings.
What is AUTL's price target?
Autolus Therapeutics (AUTL) average price target is $9.5 with a range of $8 to $11, implying a 136.91% from its last price of $4.01. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Autolus Therapeutics stock go up soon?
According to Wall Street analysts' prediction for AUTL stock, the company can go up by 136.91% (from the last price of $4.01 to the average price target of $9.5), up by 174.31% based on the highest stock price target, and up by 99.50% based on the lowest stock price target.
Can Autolus Therapeutics stock reach $6?
AUTL's average twelve months analyst stock price target of $9.5 supports the claim that Autolus Therapeutics can reach $6 in the near future.
What are Autolus Therapeutics's analysts' financial forecasts?
Autolus Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $59.38M (high $59.38M, low $59.38M), average EBITDA is $-59.38M (high $-59.38M, low $-59.38M), average net income is $-224M (high $-224M, low $-224M), average SG&A $2.38B (high $2.38B, low $2.38B), and average EPS is $-0.84 (high $-0.84, low $-0.84). AUTL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $128.33M (high $128.33M, low $128.33M), average EBITDA is $-128M (high $-128M, low $-128M), average net income is $-165M (high $-165M, low $-165M), average SG&A $5.15B (high $5.15B, low $5.15B), and average EPS is $-0.619 (high $-0.619, low $-0.619).
Did the AUTL's actual financial results beat the analysts' financial forecasts?
Based on Autolus Therapeutics's last annual report (Dec 2023), the company's revenue was $1.7M, beating the average analysts forecast of $1.5M by 13.28%. Apple's EBITDA was $-176M, beating the average prediction of $-57.402M by 205.79%. The company's net income was $-208M, missing the average estimation of $-247M by -15.57%. Apple's SG&A was $46.74M, missing the average forecast of $60.13M by -22.26%. Lastly, the company's EPS was $-1.2, beating the average prediction of $-0.993 by 20.82%. In terms of the last quarterly report (Sep 2023), Autolus Therapeutics's revenue was $406K, missing the average analysts' forecast of $624.8K by -35.02%. The company's EBITDA was $-44.014M, beating the average prediction of $-625K by 6944.49%. Autolus Therapeutics's net income was $-45.849M, missing the average estimation of $-66.384M by -30.93%. The company's SG&A was $10.61M, missing the average forecast of $25.06M by -57.66%. Lastly, the company's EPS was $-0.26, beating the average prediction of $-0.25 by 4.19%